Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 344

Sort by

Sort Order Select

Journal Articles

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, MD, Melissa Alsina, MD, Jose Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Jongphil Kim, PhD, Michael Dumala, Joel G. Turner, PhD, Daniel M Sullivan, MD

Blood (2019) 134 (Supplement_1): 3314.

https://doi.org/10.1182/blood-2019-131321

Published: 2019

Journal Articles

Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era

Ji Hyun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Ho-Sup Lee, MD PhD, Sung-Soo Yoon, MD PhD, Dong-Yeop Shin, MD PhD, Ja Min Byun, Je-Jung Lee, MD PhD, Sung-Hoon Jung, MD, Chang-Ki Min, MD PhD, Hyo Jung Kim, MD PhD, Byeong Seok Sohn, MD PhD, Sung Hwa Bae, MD, Lee Gyeong-Won, Sungwoo Park, MD, Young Rok Do, PhDMD, Hyun Jung Lee, MD, Min Kyoung Kim, Yoo Jin Lee, MD PhD

Blood (2019) 134 (Supplement_1): 4372.

https://doi.org/10.1182/blood-2019-127707

Published: 2019

Journal Articles

Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)

Sarah S. Makhani, BA, Ronit Reich-Slotky, PhD, Pashna N. Munshi, MD, Noa Biran, MD, Michele L. Donato, MD, Stuart L. Goldberg, MD, Andrew L. Pecora, MD, David S. Siegel, David H. Vesole, MD PhD, Scott D. Rowley, MD

Blood (2019) 134 (Supplement_1): 4475.

https://doi.org/10.1182/blood-2019-122111

Published: 2019

Journal Articles

Tisagenlecleucel Manufacturing Feasibility in Patients Less Than 3 Years of Age with Relapsed/Refractory Acute Lymphoblastic Leukemia

Lamis K. Eldjerou, MD, Christopher Acker, BS, Damien Howick, MSc, Lee Clough, RN, Miriam Fuchs, MD PhD, Florence Salmon, PhD, Jennifer Willert, MD, Ranjan Tiwari, MSc, Mayo Pujols, MS, Matthew Robson, MD

Blood (2019) 134 (Supplement_1): 5066.

https://doi.org/10.1182/blood-2019-127346

Published: 2019

Journal Articles

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Blood (2019) 134 (Supplement_1): 3308.

https://doi.org/10.1182/blood-2019-129684

Published: 2019

Journal Articles

Real-World Determinants of Survival in Multiple Myeloma: Experience of a Referral Center in Latin America

Aldo A Acosta-Medina, MS, Cesar Vargas-Serafin, MD, Deborah M. Martinez-Banos, Christianne Bourlon, MD

Blood (2019) 134 (Supplement_1): 5533.

https://doi.org/10.1182/blood-2019-131957

Published: 2019

Journal Articles

Treatment with Novel Agents in Patients with Multiple Myeloma in México: Data of Characteristics, Treatment Patterns and Outcomes from a Health Care System

Fernando Pérez-Jacobo, MD, Elia Zamora P., MD, Irma Leticia Barrios-Hernández, MD, Nubia Paloma Pérez-Mar, MD, Lidia Mondragón-Posadas, MD, Patricia Galindo-Delgado, MD, Magdalena Bahena-García, MD, Adrian Hernández-López, MD

Blood (2019) 134 (Supplement_1): 5562.

https://doi.org/10.1182/blood-2019-127582

Published: 2019

Journal Articles

Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Marshall McKenna, MD, Rena Feinman, PhD, Jaeil Ahn, PhD, Shuqi Wang, MSc, Elli Gourna Paleoudis, PhD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, Jun Chih Wang, MD, Abdul Rehman, MD, Giselle Alexandra Suero-Abreu, MD PhD, Phyllis McKiernan, Michele L. Donato, MD, Scott D. Rowley, MD, David S. Siegel, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 5510.

https://doi.org/10.1182/blood-2019-132134

Published: 2019

Journal Articles

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

Pashna N. Munshi, MD, Parameswaran Hari, MBBS, MD, David H. Vesole, MD PhD, Artur Jurczyszyn, MD, Jan Zaucha, MD PhD, Omar Davila, Shaji K. Kumar, MD, Nina D. Shah, MD, Muzaffar H. Qazilbash, MD, Anita D'Souza, MDMS

Blood (2019) 134 (Supplement_1): 782.

https://doi.org/10.1182/blood-2019-124804

Published: 2019

Journal Articles

Impact of Previous Cancer Therapy on Outcome of Patients with Multiple Myeloma or Smoldering Disease

Fahrettin Covut, MD, Gayathri Ravi, MD, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 3174.

https://doi.org/10.1182/blood-2019-126059

Published: 2019

Journal Articles

Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma

Smith Giri, MBBS, Ellice Y. Wong, MD, Michal Rose, MD, Roxanne Wadia, MD, Lesley S. Park, PhD MPH, Amy C. Justice, MD PhD, Natalia Neparidze, MD

Blood (2018) 132 (Supplement 1): 3162.

https://doi.org/10.1182/blood-2018-99-115633

Published: 2018

Journal Articles

Carfilzomib Cardiovascular Disease: Use of the Atherosclerotic Cardiovascular Disease Score to Predict Cardiovascular Events in Multiple Myeloma Patients Treated with Carfilzomib

Ricardo Parrondo, MD, Tracy Andrews, MSc, Rima M Panchal, MD, Sejal Kothadia, MD, Camille Johnson, MD, Jieqi Liu, Giselle Alexandra Suero-Abreu, MD PhD, David H. Vesole, MD PhD, David S Siegel, MD PhD, Noa Biran, MD

Blood (2018) 132 (Supplement 1): 3254.

https://doi.org/10.1182/blood-2018-99-113722

Published: 2018

Journal Articles

Efficacy and Safety of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma in the Era of Novel Agents

Shohei Mizuno, MD PhD, Koji Kawamura, MD PhD, Ichiro Hanamura, MD PhD, Kazutaka Sunami, MD PhD, Takehiko Mori, MD PhD, Fumihiko Nakamura, Shinsuke Iida, MD PhD, Hideyuki Nakazawa, PhD MD, Masanori Makita, Shinichi Kako, MD, Masashi Sawa, MD PhD, Yasunori Ueda, MD PhD, Hiroyuki Takahashi, MD PhD, Yoshinobu Kanda, MD PhD, Tatsuo Ichinohe, MD PhD, Yoshiko Atsuta, MD PhD, Hiroyuki Takamatsu, MD PhD, Akiyoshi Takami, MD

Blood (2018) 132 (Supplement 1): 3437.

https://doi.org/10.1182/blood-2018-99-109905

Published: 2018

Journal Articles

Osteoclast Stimulatory Transmembrane Protein ( OCSTAMP ) mRNA Levels and Clinical Variables in Persons with Plasma Cell Myeloma

Ya-Lan Zhou, MD, Jin Lu, Robert Peter Gale, Shen-Miao Yang, Li-Xin Wu, Jin-Lan Li, Ya-Zhen Qin, Yan-Rong Liu, Hao Jiang, Qian Jiang, MD, Xiaohui Zhang, MD, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Guorui Ruan

Blood (2018) 132 (Supplement 1): 5264.

https://doi.org/10.1182/blood-2018-99-116883

Published: 2018

Journal Articles

Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Noa Biran, MD, Shijia Zhang, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Michele L. Donato, MD, Alan P Skarbnik, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, David S Siegel, MD PhD

Blood (2018) 132 (Supplement 1): 2154.

https://doi.org/10.1182/blood-2018-99-114832

Published: 2018

Journal Articles

Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2018) 132 (Supplement 1): 955.

https://doi.org/10.1182/blood-2018-99-110548

Published: 2018

Journal Articles

Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients over 70 Years of Age with Younger Patients

Ning Dong, MD, David S Siegel, MD PhD, Phyllis McKiernan, Noa Biran, MD, Alan P Skarbnik, MD, David H. Vesole, MD PhD, Andrew L. Pecora, MD, Scott D. Rowley, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 4554.

https://doi.org/10.1182/blood-2018-99-117498

Published: 2018

Journal Articles

Hotspot Mutations in SF3B1 Result in Increased Alternative Splicing in Multiple Myeloma and Activation of Key Cellular Pathways

Michael A Bauer, PhD, Cody Ashby, PhD, Christopher Wardell, PhD, Maria Ortiz, Erin Flynt, Anjan Thakurta, PhD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2018-99-116858

Published: 2018

Journal Articles

20 Years of Transplant Program in Multiple Myeloma - a Single Centre Experience

Jiri Minarik, MD PhD, Edgar Faber, MD, Ludek Raida, MD PhD, Tomas Szotkowski, MD, Jaroslav Bacovsky, Tomas Pika, MD PhD, Ivana Skoumalova, MD PhD, Petra Krhovska, Jana Zapletalova, Mgr., PhD, Tomas Papajik, MD prof, Vlastimil Scudla, Prof, MD CSc

Blood (2018) 132 (Supplement 1): 5749.

https://doi.org/10.1182/blood-2018-99-112115

Published: 2018

Journal Articles

Identification of High Serum Apolipoprotein A1 As a Favorable Prognostic Indicator in Patients with Multiple Myeloma

Peng Liu, MD, Lifan Liang, Jing Li, MD

Blood (2018) 132 (Supplement 1): 5589.

https://doi.org/10.1182/blood-2018-99-110919

Published: 2018

NARROW

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era

Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)

Tisagenlecleucel Manufacturing Feasibility in Patients Less Than 3 Years of Age with Relapsed/Refractory Acute Lymphoblastic Leukemia

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Real-World Determinants of Survival in Multiple Myeloma: Experience of a Referral Center in Latin America

Treatment with Novel Agents in Patients with Multiple Myeloma in México: Data of Characteristics, Treatment Patterns and Outcomes from a Health Care System

Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

Impact of Previous Cancer Therapy on Outcome of Patients with Multiple Myeloma or Smoldering Disease

Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma

Carfilzomib Cardiovascular Disease: Use of the Atherosclerotic Cardiovascular Disease Score to Predict Cardiovascular Events in Multiple Myeloma Patients Treated with Carfilzomib

Efficacy and Safety of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma in the Era of Novel Agents

Osteoclast Stimulatory Transmembrane Protein ( OCSTAMP ) mRNA Levels and Clinical Variables in Persons with Plasma Cell Myeloma

Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients over 70 Years of Age with Younger Patients

Hotspot Mutations in SF3B1 Result in Increased Alternative Splicing in Multiple Myeloma and Activation of Key Cellular Pathways

20 Years of Transplant Program in Multiple Myeloma - a Single Centre Experience

Identification of High Serum Apolipoprotein A1 As a Favorable Prognostic Indicator in Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only